T-DXd, a next-generation ADC, has shown notable clinical activity, including improvements in ORR and OS in heavily pretreated HER2-positive GC patients, as demonstrated in DESTINY-Gastric01 and DESTINY-Gastric02 trials [89,90,91]. This evidence concerns the gene ERBB2 and gastric cancer.